Celltrion CEO to sell entire stake to multinational firm

Published: 2013-04-18 06:59:00

Updated: 2013-04-18 06:59:00

Celltrion chairman Seo Jung-jin said Tuesday he will sell his entire controlling stake in the firm to a multinational pharmaceutical company to protect the firm from short-selling by speculative investors.

“Company funds are being used to buy company shares due to short-selling by unknown grou...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK